Evidence map›Paper›PMID 38946471›Full record

ReviewExpert opinion on drug delivery2024

Understanding nanoparticle-liver interactions in nanomedicine.

Yuxin He, Yifan Wang, Lin Wang, Wen Jiang, Stefan Wilhelm

Abstract readReview
In one paragraph

Review in Expert opinion on drug delivery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Tableting of nanoparticle-based formulations for oral delivery: Enhancing biopharmaceutical performance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuxin HeStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Yifan WangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lin WangStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Wen JiangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9154-633X
Stefan WilhelmStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.ORCID 0000-0003-2167-6221

Funding

Use of 3D Quantitative Optical Methods to Optimize Mebendazole Treatment of Ovarian CancerP20GM135009 · NIGMS · UNIVERSITY OF OKLAHOMA · PI Javier Antonio Jo · 2022 to 2026
$13.6M
A novel framework for nanomedicine developmentR35GM150758 · NIGMS · UNIVERSITY OF OKLAHOMA · PI Stefan Wilhelm · 2023 to 2026
$1.5M
NIGMS NIH HHS P20 GM135009NIGMS NIH HHS R35 GM150758
6 · The paper itself

Abstract

introductionUnderstanding the interactions between administered nanoparticles and the liver is crucial for developing safe and effective nanomedicines. As the liver can sequester up to 99% of these particles due to its major phagocytic role, understanding these interactions is vital for clinical translation. AREAS COVERED: This review highlights recent studies on nanoparticle-liver interactions, including the influence of nanoparticle physicochemical properties on delivery, strategies to enhance delivery efficiency by modulating liver Kupffer cells, and their potential for treating certain hepatic diseases. Additionally, we discuss how aging impacts the liver's phagocytic functions. EXPERT OPINION: While liver accumulation can hinder nanomedicine safety and effectiveness, it also presents opportunities for treating certain liver diseases. A thorough understanding of nanoparticle-liver interactions is essential for advancing the clinical application of nanomedicines.

Indexed as

Drug Delivery SystemsKupffer CellsLiverLiver DiseasesNanomedicineNanoparticlesAgingAnimalsHumansPhagocytosisdrug deliveryliverNanomedicinenanoparticlephagocytic clearance

Identifiers

PMID38946471
PMCPMC11281865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.